---
title: UniProt release 2022_03
type: releaseNotes
date: 2022-08-03
---

# Headline

## Not just for proteins: new targets for ADP-ribosylation

ADP-ribosylation is a modification which transfers ADP-ribose from NAD(+) onto substrates. It is involved in a number of crucial functions, ranging from stress responses elicited, for example, by DNA damage and viral infection, to intra-and extracellular signaling, chromatin and transcriptional regulation, protein biosynthesis, and cell death. ADP-ribosylation of proteins has been extensively studied, and numerous enzymes catalyzing this reaction have been identified in eukaryotes. For instance the poly [ADP-ribose] polymerase [PARP1](<https://www.uniprot.org/uniprotkb?query=(gene:PARP1)%20AND%20%28reviewed:true%29>), which is activated in response to DNA damage, or the poly [ADP-ribose] polymerase tankyrases, such as [TNKS](<https://www.uniprot.org/uniprotkb?query=(gene:TNKS)%20AND%20%28reviewed:true%29>), which are involved in processes such as the Wnt signalling pathway, telomere length regulation and vesicle trafficking. A number of bacterial toxins are protein ADP-ribosyltransferases, such as [diphtheria toxin](https://www.uniprot.org/uniprotkb/P00588/entry) or [_Pseudomonas aeruginosa_ exotoxin A](https://www.uniprot.org/uniprotkb/P11439/entry), which ADP-ribosylate [eukaryotic elongation factor 2](https://www.uniprot.org/uniprotkb?facets=reviewed%3Atrue&query=%28gene%3AEEF2%29), arresting protein synthesis or [SpvB](https://www.uniprot.org/uniprotkb/P24419/entry) from _Salmonella dublin_, which ADP-ribosylates host actin, preventing its polymerization and causing actin depolymerization, cytoskeleton destruction and cytotoxicity.

But ADP-ribosylation is not just for proteins. It has been known [since at least 1999](https://pubmed.ncbi.nlm.nih.gov/10485873/) that DNA can be modified. For over 20 years, this process was investigated by the group of Keiji Wakabayashi, who was working on [pierisin](https://www.uniprot.org/uniprotkb/Q9U8Q4/entry), a cytotoxin found in late-stage larvae and pupae of the cabbage white butterfly [_Pieris rapae_](https://www.uniprot.org/taxonomy/64459). Pierisin ADP-ribosylates double-stranded DNA (dsDNA) on the N2 group of deoxyguanosine. ADP-ribosylation of DNA is detected as DNA damage by the cell machinery and leads to apoptosis. This process is thought to protect the butterfly embryo against parasitic wasps. Later on it was shown that mammalian PARP1, the well-characterized protein ADP-ribosyltransferase mentioned above, can also [modify DNA strand break termini](https://pubmed.ncbi.nlm.nih.gov/27471034/).

Recently [DarT](https://www.uniprot.org/uniprotkb/O53604/entry), another DNA-targeted ADP-ribosyltransferase, has been discovered in _Mycobacterium tuberculosis_. DarT belongs to a novel toxin-antitoxin (TA) system. It recognizes and modifies a [specific thymidine in single-stranded DNA (ssDNA) at the origin of chromosomal replication](https://pubmed.ncbi.nlm.nih.gov/27471034/), which is perceived as severe DNA damage, leading to growth arrest and eventually cell death. This effect is reversed by the [DarG](https://www.uniprot.org/uniprotkb/O53605/entry) antitoxin, which specifically removes ADP-ribosylated DNA adducts and functions as a noncanonical DNA repair factor. What is the benefit of the DarT-DarG TA system for _M. tuberculosis_? It is known that carefully controlled, slow and nonreplicating growth states are key for _M.tuberculosis_, resulting in persistent, potentially life-long infection and antibiotic tolerance. _M.tuberculosis_ has over 80 TA modules, which are thought to contribute to persistence. DarTG is the most recent addition to this arsenal.

Finally, ADP-ribosylation can also occur on single nucleosides/nucleotides. The soil bacterium [_Streptomyces coelicolor_](https://www.uniprot.org/taxonomy/100226) secretes a guanine-specific ADP-ribosyltransferase, called [ScARP](https://www.uniprot.org/uniprotkb/Q9L1E4/entry). ScARP [ADP-ribosylates guanosine and deoxyguanosine, as well as their phosphorylated derivatives GMP, dGMP, GDP, GTP, dGTP, and cyclic GMP](https://pubmed.ncbi.nlm.nih.gov/23212047/). Extracellular ScARP probably finds its guanine substrates from surrounding cells. Many bacteria use guanosine derivatives in response to environmental changes, to regulate their motility, for instance. ScARP may dysregulate these signals by direct ADP-ribosylation of guanosine derivatives, or by synthesizing ADP-ribosylguanosine as a mimicking or competitively inhibiting molecule. The presence of ADP-ribosylguanosine in the nucleotide pool might also induce genomic instability and gene mutation in competitor bacteria living near _S.coelicolor_. Chemical/biological warfare at a microscopic level!

The [non-protein targeted ADP-ribosyltransferases](<https://www.uniprot.org/uniprotkb?query=(accession:O53604)%20OR%20(accession:Q9L1E4)%20OR%20%28accession:Q9U8Q4%29>) mentioned above have all been recently updated and are available in this release of UniProtKB. While annotating these enzymes, we created many new [Rhea](https://www.rhea-db.org/) reactions, which also required the integration of new molecules at [ChEBI](https://www.ebi.ac.uk/chebi/). The interconnectedness of databases grows quickly these days!

# UniProtKB news

## Annotation of biologically relevant ligands in UniProtKB using ChEBI

UniProtKB provides descriptions of the nature and binding sites of biologically relevant ligands that are essential for protein function, such as activators, inhibitors, cofactors, and substrates. We have replaced the existing textual descriptions of these ligands with their equivalents from the [ChEBI](https://www.ebi.ac.uk/chebi) (Chemical Entities of Biological Interest) ontology to provide high quality computationally tractable annotation of biologically relevant ligands and their binding sites in proteins in UniProtKB. This enhanced dataset provides improved support for efforts to study and predict functionally relevant interactions between proteins and small molecule ligands.

The impact of this change on the UniProtKB data model is described in the following subsections.

### Deprecation of 'Calcium binding', 'Metal' and 'Nucleotide binding' annotation types

Historically, UniProtKB has described a few classes of ligand binding sites with dedicated annotation types to make it easier to query them. This has been the case for 'Calcium binding', 'Metal binding' and 'Nucleotide binding'. With the switch to the ChEBI ontology for ligand classification this is no longer necessary, and we have deprecated these annotation types and converted the existing data to ['Binding site'](https://www.uniprot.org/help/binding) annotations.

### Structuring of 'Binding site' annotations

We have structured ['Binding site'](https://www.uniprot.org/help/binding) annotations in a way that allows us to standardize the description of a ligand, and optionally the bound part of the ligand, with the ChEBI ontology. The vast majority of ligands that are curated in UniProKB are small molecules that can be represented by a ChEBI entity. A minority of curated ligands are macromolecules. These are not within the scope of ChEBI, but ChEBI contains a limited set of high-level terms (such as DNA or RNA) that we use to curate such ligands. For macromolecules and chelating structures, we sometimes (if known and of interest) also describe the bound part of the ligand with a separate ChEBI entity.

In the subsections that describe the new representation of 'Binding site' annotations in different UniProtKB formats we use the following placeholders for annotation values:

<ins>Ligand:</ins>

Placeholders for values that describe the molecule (small or macro), ion or chelating structure that is bound by the protein:

- _LigandName_: The UniProt ChEBI name of the ligand, or the word "substrate". Mandatory.
- _LigandId_: The ChEBI identifier of the ligand. Mandatory, except when the _LigandName_ is "substrate".
- _LigandLabel_: A label used to distinguish individual instances of a ligand when a protein binds multiple ligands of the same chemical nature. Optional.
- _LigandNote_: A free text note that provides further details about the ligand. Optional.

<ins>Ligand part:</ins>

Placeholders for values that describe the specific part of the ligand that is bound by the protein (e.g. the iron atom in a heme, a specific type of amino-acid residue in a protein, the 3'-CCA end of a tRNA molecule):

- _LigandPartName_: The UniProt ChEBI name of the ligand part. Optional.
- _LigandPartId_: The ChEBI identifier of the ligand part. Optional.
- _LigandPartLabel_: A label used to distinguish individual instances of a ligand part when a protein binds multiple parts of the same chemical nature that are part of the same ligand. Optional.
- _LigandPartNote_: A free text note that provides further details about the ligand part. Optional.

<ins>Additional information:</ins>

Placeholders for values that provide additional information:

- _Note_: Free text note about the binding residue(s). Optional.
- _Evidences_: List of evidences that support the annotation. Optional.

Note also that we continue to use 'Binding site' annotations primarily to describe individual amino acid residues that bind a ligand, but in order to standardize the existing ligand binding descriptions of the annotation types that have been deprecated, as well those of some ['Region'](https://www.uniprot.org/help/region) annotations, 'Binding site' annotations may now also describe a range of amino acids when the exact ligand binding residues are unknown or where adjacent ligand binding residues had been grouped in the past.

#### Text format

We have made the following changes to the UniProtKB text format to standardize the description of a ligand, and optionally the bound part of the ligand, with the ChEBI ontology.

- We have deprecated the feature types `CA_BIND`, `METAL` and `NP_BIND`.
- We have introduced eight new qualifiers for the `BINDING` feature type to describe a ligand (`/ligand`, `/ligand_id`, `/ligand_label`, `/ligand_note`) and a ligand part (`/ligand_part`, `/ligand_part_id`, `/ligand_part_label`, `/ligand_part_note`).
- The representation of the annotation _Note_ and the _Evidences_ remains unchanged.

<pre>
FT   BINDING         <code style="font-style: italic">x</code>[..<code style="font-style: italic">y</code>]
FT                   /ligand="<code style="font-style: italic">LigandName</code>"
FT                   /ligand_id="ChEBI:<code style="font-style: italic">LigandId</code>"
FT                   /ligand_label="<code style="font-style: italic">LigandLabel</code>"
FT                   /ligand_note="<code style="font-style: italic">LigandNote</code>"
FT                   /ligand_part="<code style="font-style: italic">LigandPartName</code>"
FT                   /ligand_part_id="ChEBI:<code style="font-style: italic">LigandPartId</code>"
FT                   /ligand_part_label="<code style="font-style: italic">LigandPartLabel</code>"
FT                   /ligand_part_note="<code style="font-style: italic">LigandPartNote</code>"
FT                   /note="<code style="font-style: italic">Note</code>"
FT                   /evidence="<code style="font-style: italic">Evidences</code>"
</pre>

Example: [Q9H5X1](https://rest.uniprot.org/uniprotkb/Q9H5X1.txt)

Previous format:

```
FT   METAL           89
FT                   /note="Zinc 1; shared with dimeric partner"
FT   METAL           89
FT                   /note="Zinc 2; shared with dimeric partner"
FT   METAL           123
FT                   /note="Zinc 1; shared with dimeric partner"
FT   METAL           123
FT                   /note="Zinc 2; shared with dimeric partner"
```

New format:

```
FT   BINDING         89
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="ligand shared between dimeric partners"
FT   BINDING         89
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="ligand shared between dimeric partners"
FT   BINDING         123
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="ligand shared between dimeric partners"
FT   BINDING         123
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="ligand shared between dimeric partners"
```

Example: [P39186](https://rest.uniprot.org/uniprotkb/P39186.txt)

Previous format:

```
FT   METAL           79
FT                   /note="Iron (heme C 1 axial ligand); via tele nitrogen"
FT   METAL           97
FT                   /note="Iron (heme C 1 axial ligand); via tele nitrogen"
FT   METAL           114
FT                   /note="Iron (heme C 2 axial ligand); via tele nitrogen"
FT   METAL           137
FT                   /note="Iron (heme C 2 axial ligand); via tele nitrogen"
FT   BINDING         93
FT                   /note="Heme C 1; covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779"
FT   BINDING         96
FT                   /note="Heme C 1; covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779"
FT   BINDING         133
FT                   /note="Heme C 2; covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779"
FT   BINDING         136
FT                   /note="Heme C 2; covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779"
```

New format:

```
FT   BINDING         79
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="1"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         93
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="1"
FT                   /note="covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         96
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="1"
FT                   /note="covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         97
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="1"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         114
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="2"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         133
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="2"
FT                   /note="covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         136
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="2"
FT                   /note="covalent"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
FT   BINDING         137
FT                   /ligand="heme c"
FT                   /ligand_id="ChEBI:CHEBI:61717"
FT                   /ligand_label="2"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:21419779,
FT                   ECO:0007744|PDB:3ML1"
```

Example: [Q9H6S0](https://rest.uniprot.org/uniprotkb/Q9H6S0.txt)

Previous format:

```
FT   REGION          1294..1296
FT                   /note="N6-methyladenosine residue binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5A9"
...
FT   BINDING         1310
FT                   /note="N6-methyladenosine residue"
FT                   /evidence="ECO:0000250|UniProtKB:Q96MU7"
FT   BINDING         1360
FT                   /note="N6-methyladenosine residue"
FT                   /evidence="ECO:0000250|UniProtKB:Q96MU7"
```

New format:

```
FT   BINDING         1294..1296
FT                   /ligand="RNA"
FT                   /ligand_id="ChEBI:CHEBI:33697"
FT                   /ligand_part="N(6)-methyladenosine 5'-phosphate residue"
FT                   /ligand_part_id="ChEBI:CHEBI:74449"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y5A9"
FT   BINDING         1310
FT                   /ligand="RNA"
FT                   /ligand_id="ChEBI:CHEBI:33697"
FT                   /ligand_part="N(6)-methyladenosine 5'-phosphate residue"
FT                   /ligand_part_id="ChEBI:CHEBI:74449"
FT                   /evidence="ECO:0000250|UniProtKB:Q96MU7"
FT   BINDING         1360
FT                   /ligand="RNA"
FT                   /ligand_id="ChEBI:CHEBI:33697"
FT                   /ligand_part="N(6)-methyladenosine 5'-phosphate residue"
FT                   /ligand_part_id="ChEBI:CHEBI:74449"
FT                   /evidence="ECO:0000250|UniProtKB:Q96MU7"
```

#### XML format

We have made the following changes to the [UniProtKB XSD](https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/uniprot.xsd) to standardize the description of a ligand, and optionally the bound part of the ligand, with the ChEBI ontology.

- We have deprecated the feature types `calcium-binding region`, `metal ion-binding site` and `nucleotide phosphate-binding region`.
- We have introduced two new elements, `ligand` and `ligandPart`, and corresponding types, `ligandType` and `ligandPartType`. The two types have the same structure that consists of the following four elements:
  - `name` for the value _LigandName_ / _LigandPartName_
  - `dbReference` for a cross-reference to a ChEBI record (_LigandId_ / _LigandPartId_)
  - `label` for the value _LigandLabel_ / _LigandPartLabel_
  - `note` for the value _LigandNote_ / _LigandPartNote_
- The representation of the annotation _Note_ and the _Evidences_ remains unchanged.

<pre>
    &lt;feature type="binding site" description="<code style="font-style: italic">Note</code>" evidence="<code style="font-style: italic">Evidences</code>"&gt;
      &lt;location&gt;
        ...
      &lt;/location&gt;
      &lt;ligand&gt;
        &lt;name&gt;<code style="font-style: italic">LigandName</code>&lt;/name&gt;
        &lt;dbReference type="ChEBI" id="<code style="font-style: italic">LigandId</code>"/&gt;
        &lt;label&gt;<code style="font-style: italic">LigandLabel</code>&lt;/label&gt;
        &lt;note&gt;<code style="font-style: italic">LigandNote</code>&lt;/note&gt;
      &lt;/ligand&gt;
      &lt;ligandPart&gt;
        &lt;name&gt;<code style="font-style: italic">LigandPartName</code>&lt;/name&gt;
        &lt;dbReference type="ChEBI" id="<code style="font-style: italic">LigandPartId</code>"/&gt;
        &lt;label&gt;<code style="font-style: italic">LigandPartLabel</code>&lt;/label&gt;
        &lt;note&gt;<code style="font-style: italic">LigandPartNote</code>&lt;/note&gt;
      &lt;/ligandPart&gt;
    &lt;/feature&gt;
</pre>

The XSD changes are highlighted in red color below:

<pre>
    &lt;!-- Feature definition begins --&gt;
    &lt;xs:complexType name="featureType"&gt;
    ...
        &lt;xs:sequence&gt;
        ...
            &lt;xs:element name="location" type="locationType"&gt;
                &lt;xs:annotation&gt;
                    &lt;xs:documentation&gt;Describes the sequence coordinates of the annotation.&lt;/xs:documentation&gt;
                &lt;/xs:annotation&gt;
            &lt;/xs:element&gt;
            <code style="color:red">&lt;xs:element name="ligand" type="ligandType" minOccurs="0"&gt;
                &lt;xs:annotation&gt;
                    &lt;xs:documentation&gt;Describes the chemical entity that is bound in annotations that describe binding sites.&lt;/xs:documentation&gt;
                &lt;/xs:annotation&gt;
            &lt;/xs:element&gt;
            &lt;xs:element name="ligandPart" type="ligandPartType" minOccurs="0"&gt;
                &lt;xs:annotation&gt;
                    &lt;xs:documentation&gt;Describes the specific part of a molecule that is bound in annotations that describe binding sites.&lt;/xs:documentation&gt;
                &lt;/xs:annotation&gt;
            &lt;/xs:element&gt;</code>
        &lt;/xs:sequence&gt;
        &lt;xs:attribute name="type" use="required"&gt;
        ...
            &lt;xs:simpleType&gt;
                &lt;xs:restriction base="xs:string"&gt;
                    &lt;xs:enumeration value="active site"/&gt;
                    &lt;xs:enumeration value="binding site"/&gt;
                    <code style="color:red">&lt;!-- &lt;xs:enumeration value="calcium-binding region"/&gt; --&gt;</code>
                    ...
                    <code style="color:red">&lt;!-- &lt;xs:enumeration value="metal ion-binding site"/&gt; --&gt;</code>
                    ...
                    <code style="color:red">&lt;!-- &lt;xs:enumeration value="nucleotide phosphate-binding region"/&gt; --&gt;</code>
                    ...
                &lt;/xs:restriction&gt;
            &lt;/xs:simpleType&gt;
        &lt;/xs:attribute&gt;
    ...
    &lt;/xs:complexType&gt;
    ...
    <code style="color:red">&lt;xs:complexType name="ligandType"&gt;
        &lt;xs:annotation&gt;
            &lt;xs:documentation&gt;Describes a ligand.&lt;/xs:documentation&gt;
        &lt;/xs:annotation&gt;
        &lt;xs:sequence&gt;
            &lt;xs:element name="name" type="xs:string"/&gt;
            &lt;xs:element name="dbReference" type="dbReferenceType" minOccurs="0"/&gt;
            &lt;xs:element name="label" type="xs:string" minOccurs="0"/&gt;
            &lt;xs:element name="note" type="xs:string" minOccurs="0"/&gt;
        &lt;/xs:sequence&gt;
    &lt;/xs:complexType&gt;

    &lt;xs:complexType name="ligandPartType"&gt;
        &lt;xs:annotation&gt;
            &lt;xs:documentation&gt;Describes a ligand part.&lt;/xs:documentation&gt;
        &lt;/xs:annotation&gt;
        &lt;xs:sequence&gt;
            &lt;xs:element name="name" type="xs:string"/&gt;
            &lt;xs:element name="dbReference" type="dbReferenceType" minOccurs="0"/&gt;
            &lt;xs:element name="label" type="xs:string" minOccurs="0"/&gt;
            &lt;xs:element name="note" type="xs:string" minOccurs="0"/&gt;
        &lt;/xs:sequence&gt;
    &lt;/xs:complexType&gt;</code>
</pre>

Example: [Q9H5X1](https://rest.uniprot.org/uniprotkb/Q9H5X1.xml)

Previous format:

```
    <feature type="metal ion-binding site" description="Zinc 1; shared with dimeric partner">
      <location>
        <position position="89"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Zinc 2; shared with dimeric partner">
      <location>
        <position position="89"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Zinc 1; shared with dimeric partner">
      <location>
        <position position="123"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Zinc 2; shared with dimeric partner">
      <location>
        <position position="123"/>
      </location>
    </feature>
```

New format:

```
    <feature type="binding site">
      <location>
        <position position="89"/>
      </location>
      <ligand>
        <name>Zn(2+)</name>
        <dbReference type="ChEBI" id="CHEBI:29105"/>
        <label>1</label>
        <note>ligand shared between dimeric partners</note>
      </ligand>
    </feature>
    <feature type="binding site">
      <location>
        <position position="89"/>
      </location>
      <ligand>
        <name>Zn(2+)</name>
        <dbReference type="ChEBI" id="CHEBI:29105"/>
        <label>2</label>
        <note>ligand shared between dimeric partners</note>
      </ligand>
    </feature>
    <feature type="binding site">
      <location>
        <position position="123"/>
      </location>
      <ligand>
        <name>Zn(2+)</name>
        <dbReference type="ChEBI" id="CHEBI:29105"/>
        <label>1</label>
        <note>ligand shared between dimeric partners</note>
      </ligand>
    </feature>
    <feature type="binding site">
      <location>
        <position position="123"/>
      </location>
      <ligand>
        <name>Zn(2+)</name>
        <dbReference type="ChEBI" id="CHEBI:29105"/>
        <label>2</label>
        <note>ligand shared between dimeric partners</note>
      </ligand>
    </feature>
```

Example: [P39186](https://rest.uniprot.org/uniprotkb/P39186.xml)

Previous format:

```
    <feature type="metal ion-binding site" description="Iron (heme C 1 axial ligand); via tele nitrogen">
      <location>
        <position position="79"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Iron (heme C 1 axial ligand); via tele nitrogen">
      <location>
        <position position="97"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Iron (heme C 2 axial ligand); via tele nitrogen">
      <location>
        <position position="114"/>
      </location>
    </feature>
    <feature type="metal ion-binding site" description="Iron (heme C 2 axial ligand); via tele nitrogen">
      <location>
        <position position="137"/>
      </location>
    </feature>
    <feature type="binding site" description="Heme C 1; covalent" evidence="2">
      <location>
        <position position="93"/>
      </location>
    </feature>
    <feature type="binding site" description="Heme C 1; covalent" evidence="2">
      <location>
        <position position="96"/>
      </location>
    </feature>
    <feature type="binding site" description="Heme C 2; covalent" evidence="2">
      <location>
        <position position="133"/>
      </location>
    </feature>
    <feature type="binding site" description="Heme C 2; covalent" evidence="2">
      <location>
        <position position="136"/>
      </location>
    </feature>
```

New format:

```
    <feature type="binding site" description="axial binding residue" evidence="2 5">
      <location>
        <position position="79"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>1</label>
      </ligand>
      <ligandPart>
        <name>Fe</name>
        <dbReference type="ChEBI" id="CHEBI:18248"/>
      </ligandPart>
    </feature>
    <feature type="binding site" description="covalent" evidence="2 5">
      <location>
        <position position="93"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>1</label>
      </ligand>
    </feature>
    <feature type="binding site" description="covalent" evidence="2 5">
      <location>
        <position position="96"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>1</label>
      </ligand>
    </feature>
    <feature type="binding site" description="axial binding residue" evidence="2 5">
      <location>
        <position position="97"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>1</label>
      </ligand>
      <ligandPart>
        <name>Fe</name>
        <dbReference type="ChEBI" id="CHEBI:18248"/>
      </ligandPart>
    </feature>
    <feature type="binding site" description="axial binding residue" evidence="2 5">
      <location>
        <position position="114"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>2</label>
      </ligand>
      <ligandPart>
        <name>Fe</name>
        <dbReference type="ChEBI" id="CHEBI:18248"/>
      </ligandPart>
    </feature>
    <feature type="binding site" description="covalent" evidence="2 5">
      <location>
        <position position="133"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>2</label>
      </ligand>
    </feature>
    <feature type="binding site" description="covalent" evidence="2 5">
      <location>
        <position position="136"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>2</label>
      </ligand>
    </feature>
    <feature type="binding site" description="axial binding residue" evidence="2 5">
      <location>
        <position position="137"/>
      </location>
      <ligand>
        <name>heme c</name>
        <dbReference type="ChEBI" id="CHEBI:61717"/>
        <label>2</label>
      </ligand>
      <ligandPart>
        <name>Fe</name>
        <dbReference type="ChEBI" id="CHEBI:18248"/>
      </ligandPart>
    </feature>
```

Example: [Q9H6S0](https://rest.uniprot.org/uniprotkb/Q9H6S0.xml)

Previous format:

```
    <feature type="region of interest" description="N6-methyladenosine residue binding" evidence="3">
      <location>
        <begin position="1294"/>
        <end position="1296"/>
      </location>
    </feature>
    ...
    <feature type="binding site" description="N6-methyladenosine residue" evidence="2">
      <location>
        <position position="1310"/>
      </location>
    </feature>
    <feature type="binding site" description="N6-methyladenosine residue" evidence="2">
      <location>
        <position position="1360"/>
      </location>
    </feature>
```

New format:

```
    <feature type="binding site" evidence="3">
      <location>
        <begin position="1294"/>
        <end position="1296"/>
      </location>
      <ligand>
        <name>RNA</name>
        <dbReference type="ChEBI" id="CHEBI:33697"/>
      </ligand>
      <ligandPart>
        <name>N(6)-methyladenosine 5'-phosphate residue</name>
        <dbReference type="ChEBI" id="CHEBI:74449"/>
      </ligandPart>
    </feature>
    <feature type="binding site" evidence="2">
      <location>
        <position position="1310"/>
      </location>
      <ligand>
        <name>RNA</name>
        <dbReference type="ChEBI" id="CHEBI:33697"/>
      </ligand>
      <ligandPart>
        <name>N(6)-methyladenosine 5'-phosphate residue</name>
        <dbReference type="ChEBI" id="CHEBI:74449"/>
      </ligandPart>
    </feature>
    <feature type="binding site" evidence="2">
      <location>
        <position position="1360"/>
      </location>
      <ligand>
        <name>RNA</name>
        <dbReference type="ChEBI" id="CHEBI:33697"/>
      </ligand>
      <ligandPart>
        <name>N(6)-methyladenosine 5'-phosphate residue</name>
        <dbReference type="ChEBI" id="CHEBI:74449"/>
      </ligandPart>
    </feature>
```

#### RDF format

We have made the following changes to the [UniProt RDF schema ontology](https://ftp.uniprot.org/pub/databases/uniprot/current_release/rdf/core.owl) to standardize the description of a ligand, and optionally the bound part of the ligand, with the ChEBI ontology.

- We have deprecated the classes `Calcium_Binding_Annotation`, `Metal_Binding_Annotation` and `NP_Binding_Annotation`.
- We have introduced two new properties, `ligand` and `ligandPart`, whose `rdfs:domain` is the [`Binding_Site_Annotation`](http://purl.uniprot.org/core/Binding_Site_Annotation) class. The nature of a ligand or ligand part is described as one of:
  - an `rdfs:subClassOf` of the corresponding ChEBI class (when a ChEBI identifier is available)
  - a class identified by an entry URI fragment whose identifier is generated from the ligand (part) name (when no ChEBI identifier is available)
- A `partOf` statement is used to link a ligand part class to the ligand class that contains the part. As a consequence, the [`partOf`](http://purl.uniprot.org/core/partOf) property will loose its `rdfs:domain` and `rdfs:range`.
- The label and note of a ligand (_LigandLabel_, _LigandNote_) or ligand part (_LigandPartLabel_, _LigandPartNote_) are described at the corresponding class level with `rdfs:label` and `rdfs:comment` statements, respectively.
- The representation of the annotation _Note_ and the _Evidences_ remains unchanged.

In the examples below, the parts of the annotation whose structure has not changed (details of sequence range, evidences) are omitted.

Example: [Q9H5X1](https://rest.uniprot.org/uniprotkb/Q9H5X1.ttl)

Previous format:

```
<Q9H5X1> rdf:type up:Protein ;
...
  up:annotation ...
    <Q9H5X1#SIP205C589B1B82C19D> ,
    <Q9H5X1#SIP0FDA08578DA645F1> ,
    <Q9H5X1#SIPF931DC9BFE3EE1EA> ,
    <Q9H5X1#SIP9FE49AAED1489740> ,
...
<Q9H5X1#SIP205C589B1B82C19D>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Zinc 1; shared with dimeric partner" ;
  up:range range:22862455408963886tt89tt89 .
...
<Q9H5X1#SIP0FDA08578DA645F1>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Zinc 2; shared with dimeric partner" ;
  up:range range:22862455408963886tt89tt89 .
<Q9H5X1#SIPF931DC9BFE3EE1EA>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Zinc 1; shared with dimeric partner" ;
  up:range range:22862455408963886tt123tt123 .
...
<Q9H5X1#SIP9FE49AAED1489740>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Zinc 2; shared with dimeric partner" ;
  up:range range:22862455408963886tt123tt123 .
```

New format:

```
<Q9H5X1> rdf:type up:Protein ;
...
  up:annotation ...
    <Q9H5X1#SIPEF929039F510ECEF> ,
    <Q9H5X1#SIP920EDE1AF7D0C789> ,
    <Q9H5X1#SIP72E42A3FB2BD4B9A> ,
    <Q9H5X1#SIP34635D3021CE14FA> ,
...
<Q9H5X1#SIPEF929039F510ECEF>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H5X1#SIPA9D42F70EC978DA2> ;
  up:range range:22862455408963886tt89tt89 .
...
<Q9H5X1#SIP920EDE1AF7D0C789>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H5X1#SIP2113E97BF945072A> ;
  up:range range:22862455408963886tt89tt89 .
<Q9H5X1#SIP72E42A3FB2BD4B9A>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H5X1#SIPA9D42F70EC978DA2> ;
  up:range range:22862455408963886tt123tt123 .
...
<Q9H5X1#SIP34635D3021CE14FA>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H5X1#SIP2113E97BF945072A> ;
  up:range range:22862455408963886tt123tt123 .
...
<Q9H5X1#SIPA9D42F70EC978DA2>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_29105> ;
  rdfs:label "1" ;
  rdfs:comment "ligand shared between dimeric partners" .
<Q9H5X1#SIP2113E97BF945072A>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_29105> ;
  rdfs:label "2" ;
  rdfs:comment "ligand shared between dimeric partners" .
```

Example: [P39186](https://rest.uniprot.org/uniprotkb/P39186.ttl)

Previous format:

```
<P39186> rdf:type up:Protein ;
...
  up:annotation ...
    <P39186#SIP2FA351DB0B3C2F16> ,
    <P39186#SIP68C53D2ADFC188FB> ,
    <P39186#SIP293BA29AFBE6705D> ,
    <P39186#SIP04086D3B0200EFDB> ,
    <P39186#SIP421DBD60EE668E9A> ,
    <P39186#SIPBE78F7D7D1DFDB96> ,
    <P39186#SIPF42DD8F9E97D4C04> ,
    <P39186#SIP67D0B11099583DF4> ,
...
<P39186#SIP2FA351DB0B3C2F16>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Iron (heme C 1 axial ligand); via tele nitrogen" ;
  up:range range:22574318868772398tt79tt79 .
...
<P39186#SIP68C53D2ADFC188FB>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Iron (heme C 1 axial ligand); via tele nitrogen" ;
  up:range range:22574318868772398tt97tt97 .
...
<P39186#SIP293BA29AFBE6705D>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Iron (heme C 2 axial ligand); via tele nitrogen" ;
  up:range range:22574318868772398tt114tt114 .
...
<P39186#SIP04086D3B0200EFDB>
  rdf:type up:Metal_Binding_Annotation ;
  rdfs:comment "Iron (heme C 2 axial ligand); via tele nitrogen" ;
  up:range range:22574318868772398tt137tt137 .
...
<P39186#SIP421DBD60EE668E9A>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "Heme C 1; covalent" ;
  up:range range:22574318868772398tt93tt93 .
...
<P39186#SIPBE78F7D7D1DFDB96>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "Heme C 1; covalent" ;
  up:range range:22574318868772398tt96tt96 .
...
<P39186#SIPF42DD8F9E97D4C04>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "Heme C 2; covalent" ;
  up:range range:22574318868772398tt133tt133 .
...
<P39186#SIP67D0B11099583DF4>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "Heme C 2; covalent" ;
  up:range range:22574318868772398tt136tt136 .
```

New format:

```
<P39186> rdf:type up:Protein ;
...
  up:annotation ...
    <P39186#SIP6B05083539025B03> ,
    <P39186#SIP26EC788A934C8F47> ,
    <P39186#SIPE6A28D6EA4C9FD5D> ,
    <P39186#SIPFBD274DC3C6C2D4D> ,
    <P39186#SIP35F10B423DCD5ABF> ,
    <P39186#SIP2B84A319ABAB6D10> ,
    <P39186#SIP3DF7879BD48FFB15> ,
    <P39186#SIP4B946529653D1444> ,
...
<P39186#SIP6B05083539025B03>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "axial binding residue" ;
  up:ligand <P39186#SIP03157F908F4B7F18> ;
  up:ligandPart <P39186#SIP85C37483D3E0B42A> ;
  up:range range:22574318868772398tt79tt79 .
...
<P39186#SIP26EC788A934C8F47>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "covalent" ;
  up:ligand <P39186#SIP03157F908F4B7F18> ;
  up:range range:22574318868772398tt93tt93 .
...
<P39186#SIPE6A28D6EA4C9FD5D>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "covalent" ;
  up:ligand <P39186#SIP03157F908F4B7F18> ;
  up:range range:22574318868772398tt96tt96 .
...
<P39186#SIPFBD274DC3C6C2D4D>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "axial binding residue" ;
  up:ligand <P39186#SIP03157F908F4B7F18> ;
  up:ligandPart <P39186#SIP85C37483D3E0B42A> ;
  up:range range:22574318868772398tt97tt97 .
...
<P39186#SIP35F10B423DCD5ABF>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "axial binding residue" ;
  up:ligand <P39186#SIP997F95171519AEFE> ;
  up:ligandPart <P39186#SIP428C6123B1B272B9> ;
  up:range range:22574318868772398tt114tt114 .
...
<P39186#SIP2B84A319ABAB6D10>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "covalent" ;
  up:ligand <P39186#SIP997F95171519AEFE> ;
  up:range range:22574318868772398tt133tt133 .
...
<P39186#SIP3DF7879BD48FFB15>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "covalent" ;
  up:ligand <P39186#SIP997F95171519AEFE> ;
  up:range range:22574318868772398tt136tt136 .
...
<P39186#SIP4B946529653D1444>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "axial binding residue" ;
  up:ligand <P39186#SIP997F95171519AEFE> ;
  up:ligandPart <P39186#SIP428C6123B1B272B9> ;
  up:range range:22574318868772398tt137tt137 .
...
<P39186#SIP03157F908F4B7F18>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_61717> ;
  rdfs:label "1" .
<P39186#SIP85C37483D3E0B42A>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_18248> ;
  up:partOf <P39186#SIP03157F908F4B7F18>.
<P39186#SIP997F95171519AEFE>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_61717> ;
  rdfs:label "2" .
<P39186#SIP428C6123B1B272B9>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_18248> ;
  up:partOf <P39186#SIP997F95171519AEFE>.
```

Example: [Q9H6S0](https://rest.uniprot.org/uniprotkb/Q9H6S0.ttl)

Previous format:

```
<Q9H6S0> rdf:type up:Protein ;
...
  up:annotation ...
    <Q9H6S0#SIP1A82C4FF56746BB8> ,
...
    <Q9H6S0#SIPBD815A286DC38CC5> ,
    <Q9H6S0#SIPC5465EB9289C0B15> ,
...
<Q9H6S0#SIP1A82C4FF56746BB8>
  rdf:type up:Region_Annotation ;
  rdfs:comment "N6-methyladenosine residue binding" ;
  up:range range:22862455425413166tt1294tt1296 .
...
<Q9H6S0#SIPBD815A286DC38CC5>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "N6-methyladenosine residue" ;
  up:range range:22862455425413166tt1310tt1310 .
...
<Q9H6S0#SIPC5465EB9289C0B15>
  rdf:type up:Binding_Site_Annotation ;
  rdfs:comment "N6-methyladenosine residue" ;
  up:range range:22862455425413166tt1360tt1360 .
```

New format:

```
<Q9H6S0> rdf:type up:Protein ;
...
  up:annotation ...
    <Q9H6S0#SIP422D37614A6D5721> ,
    <Q9H6S0#SIP181E7990DC5C18D8> ,
    <Q9H6S0#SIP21050F3BB73E81A2> ,
...
<Q9H6S0#SIP422D37614A6D5721>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H6S0#SIPC276DB5E970331C9> ;
  up:ligandPart <Q9H6S0#SIP93E43149D18FF63B> ;
  up:range range:22862455425413166tt1294tt1296 .
...
<Q9H6S0#SIP181E7990DC5C18D8>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H6S0#SIPC276DB5E970331C9> ;
  up:ligandPart <Q9H6S0#SIP93E43149D18FF63B> ;
  up:range range:22862455425413166tt1310tt1310 .
...
<Q9H6S0#SIP21050F3BB73E81A2>
  rdf:type up:Binding_Site_Annotation ;
  up:ligand <Q9H6S0#SIPC276DB5E970331C9> ;
  up:ligandPart <Q9H6S0#SIP93E43149D18FF63B> ;
  up:range range:22862455425413166tt1360tt1360 .
...
<Q9H6S0#SIPC276DB5E970331C9>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_33697>.
<Q9H6S0#SIP93E43149D18FF63B>
  rdfs:subClassOf <http://purl.obolibrary.org/obo/CHEBI_74449> ;
  up:partOf <Q9H6S0#SIPC276DB5E970331C9>.
```

## Changes to the [controlled vocabulary of human diseases](https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/docs/humdisease)

New diseases:

- [Agammaglobulinemia 9, autosomal recessive](https://www.uniprot.org/diseases/DI-06309)
- [Agammaglobulinemia 10, autosomal dominant](https://www.uniprot.org/diseases/DI-06310)
- [Anemia, congenital dyserythropoietic, 3A](https://www.uniprot.org/diseases/DI-06363)
- [Anemia, congenital dyserythropoietic, 3B, autosomal recessive](https://www.uniprot.org/diseases/DI-06364)
- [Brunet-Wagner neurodevelopmental syndrome](https://www.uniprot.org/diseases/DI-06308)
- [Bryant-Li-Bhoj neurodevelopmental syndrome 1](https://www.uniprot.org/diseases/DI-06327)
- [Bryant-Li-Bhoj neurodevelopmental syndrome 2](https://www.uniprot.org/diseases/DI-06328)
- [Cardiomyopathy, dilated 2F](https://www.uniprot.org/diseases/DI-06345)
- [Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism](https://www.uniprot.org/diseases/DI-06352)
- [Charcot-Marie-Tooth disease, demyelinating, 1I](https://www.uniprot.org/diseases/DI-06335)
- [Charcot-Marie-Tooth disease, demyelinating, 1H](https://www.uniprot.org/diseases/DI-06336)
- [Combined oxidative phosphorylation deficiency 54](https://www.uniprot.org/diseases/DI-06332)
- [Combined oxidative phosphorylation deficiency 55](https://www.uniprot.org/diseases/DI-06333)
- [Congenital disorder of deglycosylation 2](https://www.uniprot.org/diseases/DI-06360)
- [Congenital disorder of glycosylation 1W, autosomal dominant](https://www.uniprot.org/diseases/DI-06319)
- [Craniofacial microsomia](https://www.uniprot.org/diseases/DI-06354)
- [Craniotubular dysplasia, Ikegawa type](https://www.uniprot.org/diseases/DI-06325)
- [Deafness, autosomal dominant, 82](https://www.uniprot.org/diseases/DI-06372)
- [Developmental and epileptic encephalopathy 100](https://www.uniprot.org/diseases/DI-06361)
- [Developmental and epileptic encephalopathy 101](https://www.uniprot.org/diseases/DI-06373)
- [Developmental delay with variable neurologic and brain abnormalities](https://www.uniprot.org/diseases/DI-06311)
- [Dystonia 33](https://www.uniprot.org/diseases/DI-06304)
- [Dystonia 34, myoclonic](https://www.uniprot.org/diseases/DI-06323)
- [Dystonia, early-onset, and/or spastic paraplegia](https://www.uniprot.org/diseases/DI-06301)
- [Epidermolysis bullosa, junctional 2A, intermediate](https://www.uniprot.org/diseases/DI-06337)
- [Epidermolysis bullosa, junctional 2B, severe](https://www.uniprot.org/diseases/DI-06338)
- [Epidermolysis bullosa, junctional 3A, intermediate](https://www.uniprot.org/diseases/DI-06340)
- [Epidermolysis bullosa, junctional 3B, severe](https://www.uniprot.org/diseases/DI-06339)
- [Epidermolysis bullosa, junctional 4, intermediate](https://www.uniprot.org/diseases/DI-06341)
- [Epidermolysis bullosa, junctional 5A, intermediate](https://www.uniprot.org/diseases/DI-06342)
- [Epidermolysis bullosa, junctional 6, with pyloric atresia](https://www.uniprot.org/diseases/DI-06343)
- [Ferguson-Bonni neurodevelopmental syndrome](https://www.uniprot.org/diseases/DI-06315)
- [Gastrointestinal defects and immunodeficiency syndrome 2](https://www.uniprot.org/diseases/DI-06318)
- [Hyper-IgE recurrent infection syndrome 4A, autosomal dominant](https://www.uniprot.org/diseases/DI-06348)
- [Hypogonadotropic hypogonadism 26 with or without anosmia](https://www.uniprot.org/diseases/DI-06321)
- [Hypogonadotropic hypogonadism 27 without anosmia](https://www.uniprot.org/diseases/DI-06349)
- [Immunodeficiency 93 and hypertrophic cardiomyopathy](https://www.uniprot.org/diseases/DI-06317)
- [Immunodeficiency 94 with autoinflammation and dysmorphic facies](https://www.uniprot.org/diseases/DI-06346)
- [Immunodeficiency 95](https://www.uniprot.org/diseases/DI-06358)
- [Immunodeficiency 96](https://www.uniprot.org/diseases/DI-06359)
- [Inclusion body myopathy and brain white matter abnormalities](https://www.uniprot.org/diseases/DI-06329)
- [Intellectual developmental disorder, autosomal recessive 73](https://www.uniprot.org/diseases/DI-06320)
- [Intellectual developmental disorder, FRA12A type](https://www.uniprot.org/diseases/DI-06375)
- [Intellectual disability and myopathy syndrome](https://www.uniprot.org/diseases/DI-06322)
- [Kury-Isidor syndrome](https://www.uniprot.org/diseases/DI-06353)
- [Leukoencephalopathy, hereditary diffuse, with spheroids 2](https://www.uniprot.org/diseases/DI-06298)
- [Leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy](https://www.uniprot.org/diseases/DI-06305)
- [Macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin](https://www.uniprot.org/diseases/DI-06356)
- [Mitochondrial DNA depletion syndrome 20, MNGIE type](https://www.uniprot.org/diseases/DI-06362)
- [Mucopolysaccharidosis 10](https://www.uniprot.org/diseases/DI-06314)
- [Myopia 28, autosomal recessive](https://www.uniprot.org/diseases/DI-06357)
- [Neurodevelopmental disorder with central hypotonia and dysmorphic facies](https://www.uniprot.org/diseases/DI-06368)
- [Neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis](https://www.uniprot.org/diseases/DI-06302)
- [Neurodevelopmental disorder with or without variable movement or behavioral abnormalities](https://www.uniprot.org/diseases/DI-06324)
- [Noonan syndrome 14](https://www.uniprot.org/diseases/DI-06344)
- [Oculopharyngodistal myopathy 4](https://www.uniprot.org/diseases/DI-06365)
- [Oocyte maturation defect 12](https://www.uniprot.org/diseases/DI-06313)
- [Osteogenesis imperfecta 22](https://www.uniprot.org/diseases/DI-06367)
- [Parkinsonism-dystonia 3, childhood-onset](https://www.uniprot.org/diseases/DI-06334)
- [Pulmonary fibrosis, and/or bone marrow failure, telomere-related, 6](https://www.uniprot.org/diseases/DI-06355)
- [Rauch-Steindl syndrome](https://www.uniprot.org/diseases/DI-06312)
- [Restrictive dermopathy 2](https://www.uniprot.org/diseases/DI-06366)
- [Rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunction](https://www.uniprot.org/diseases/DI-06374)
- [Spastic paraplegia 85, autosomal recessive](https://www.uniprot.org/diseases/DI-06303)
- [Spastic paraplegia 86, autosomal recessive](https://www.uniprot.org/diseases/DI-06330)
- [Spermatogenic failure 64](https://www.uniprot.org/diseases/DI-06306)
- [Spermatogenic failure 65](https://www.uniprot.org/diseases/DI-06307)
- [Spermatogenic failure 66](https://www.uniprot.org/diseases/DI-06369)
- [Spermatogenic failure 67](https://www.uniprot.org/diseases/DI-06370)
- [Spermatogenic failure 68](https://www.uniprot.org/diseases/DI-06371)
- [Stuve-Wiedemann syndrome 2](https://www.uniprot.org/diseases/DI-06347)
- [Teebi hypertelorism syndrome 2](https://www.uniprot.org/diseases/DI-06331)
- [Tessadori-van Haaften neurodevelopmental syndrome 1](https://www.uniprot.org/diseases/DI-06350)
- [Tessadori-van Haaften neurodevelopmental syndrome 2](https://www.uniprot.org/diseases/DI-06351)
- [Thrombophilia 13, X-linked, due to factor VIII defect](https://www.uniprot.org/diseases/DI-06326)
- [Trichothiodystrophy 8, non-photosensitive](https://www.uniprot.org/diseases/DI-06299)
- [Trichothiodystrophy 9, non-photosensitive](https://www.uniprot.org/diseases/DI-06300)
- [Yoon-Bellen neurodevelopmental syndrome](https://www.uniprot.org/diseases/DI-06316)

Modified diseases:

- Alacrima, achalasia, and mental retardation syndrome -> [Alacrima, achalasia, and intellectual disability syndrome](https://www.uniprot.org/diseases/DI-03937)
- Alopecia-mental retardation syndrome 1 -> [Alopecia-intellectual disability syndrome 1](https://www.uniprot.org/diseases/DI-05180)
- Alpha-thalassemia mental retardation syndrome, X-linked -> [Alpha-thalassemia/intellectual disability syndrome, X-linked](https://www.uniprot.org/diseases/DI-02428)
- Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis -> [AMME complex](https://www.uniprot.org/diseases/DI-01183)
- Arthrogryposis, mental retardation, and seizures -> [Arthrogryposis, intellectual disability, and seizures](https://www.uniprot.org/diseases/DI-03977)
- Brody myopathy -> [Brody disease](https://www.uniprot.org/diseases/DI-00200)
- Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 -> [Cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1](https://www.uniprot.org/diseases/DI-02742)
- Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2 -> [Cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 2](https://www.uniprot.org/diseases/DI-03450)
- Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 3 -> [Cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 3](https://www.uniprot.org/diseases/DI-02743)
- Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4 -> [Cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4](https://www.uniprot.org/diseases/DI-03773)
- Cerebellar ataxia, non-progressive, with mental retardation -> [Cerebellar dysfunction with variable cognitive and behavioral abnormalities](https://www.uniprot.org/diseases/DI-03530)
- Cleft palate, cardiac defects, and mental retardation -> [Cleft palate, cardiac defects, and intellectual disability](https://www.uniprot.org/diseases/DI-05007)
- Coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation and ear anomalies syndrome -> [Coloboma, congenital heart disease, ichthyosiform dermatosis, intellectual disability and ear anomalies syndrome](https://www.uniprot.org/diseases/DI-03465)
- Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation -> [Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or intellectual disability](https://www.uniprot.org/diseases/DI-04066)
- Congenital central hypoventilation syndrome -> [Central hypoventilation syndrome, congenital, 1](https://www.uniprot.org/diseases/DI-01391)
- Congenital disorder of deglycosylation -> [Congenital disorder of deglycosylation 1](https://www.uniprot.org/diseases/DI-03774)
- Craniofacial dysmorphism, skeletal anomalies and mental retardation syndrome -> [Craniofacial dysmorphism, skeletal anomalies and intellectual disability syndrome](https://www.uniprot.org/diseases/DI-03178)
- Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome -> [Deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures syndrome](https://www.uniprot.org/diseases/DI-03992)
- Develomental and epileptic encephalopathy 94 -> [Developmental and epileptic encephalopathy 94](https://www.uniprot.org/diseases/DI-03857)
- Epidermolysis bullosa simplex, with migratory circinate erythema -> [Epidermolysis bullosa simplex 2E, with migratory circinate erythema](https://www.uniprot.org/diseases/DI-00466)
- Epidermolysis bullosa simplex, with mottled pigmentation -> [Epidermolysis bullosa simplex 2F, with mottled pigmentation](https://www.uniprot.org/diseases/DI-00467)
- Epilepsy, hearing loss, and mental retardation syndrome -> [Neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities](https://www.uniprot.org/diseases/DI-04554)
- Gastrointestinal defects and immunodeficiency syndrome -> [Gastrointestinal defects and immunodeficiency syndrome 1](https://www.uniprot.org/diseases/DI-03733)
- Hyperphosphatasia with mental retardation syndrome 1 -> [Hyperphosphatasia with intellectual disability syndrome 1](https://www.uniprot.org/diseases/DI-02921)
- Hyperphosphatasia with mental retardation syndrome 2 -> [Hyperphosphatasia with intellectual disability syndrome 2](https://www.uniprot.org/diseases/DI-03510)
- Hyperphosphatasia with mental retardation syndrome 3 -> [Hyperphosphatasia with intellectual disability syndrome 3](https://www.uniprot.org/diseases/DI-03720)
- Hyperphosphatasia with mental retardation syndrome 4 -> [Hyperphosphatasia with intellectual disability syndrome 4](https://www.uniprot.org/diseases/DI-04049)
- Hyperphosphatasia with mental retardation syndrome 6 -> [Hyperphosphatasia with intellectual disability syndrome 6](https://www.uniprot.org/diseases/DI-04648)
- Hypomagnesemia, seizures, and mental retardation 1 -> [Hypomagnesemia, seizures, and intellectual disability 1](https://www.uniprot.org/diseases/DI-04456)
- Hypomagnesemia, seizures, and mental retardation 2 -> [Hypomagnesemia, seizures, and intellectual disability 2](https://www.uniprot.org/diseases/DI-05475)
- Ichthyosis, spastic quadriplegia, and mental retardation -> [Ichthyosis, spastic quadriplegia, and intellectual disability](https://www.uniprot.org/diseases/DI-03376)
- Leukoencephalopathy, diffuse hereditary, with spheroids -> [Leukoencephalopathy, hereditary diffuse, with spheroids 1](https://www.uniprot.org/diseases/DI-03392)
- Mental retardation, anterior maxillary protrusion, and strabismus -> [Intellectual disability, anterior maxillary protrusion, and strabismus](https://www.uniprot.org/diseases/DI-02951)
- Mental retardation, aphasia, shuffling gait, and adducted thumbs syndrome -> [MASA syndrome](https://www.uniprot.org/diseases/DI-00707)
- Mental retardation, autosomal dominant 1 -> [Intellectual developmental disorder, autosomal dominant 1](https://www.uniprot.org/diseases/DI-00710)
- Mental retardation, autosomal dominant 10 -> [Intellectual developmental disorder, autosomal dominant 10](https://www.uniprot.org/diseases/DI-03253)
- Mental retardation, autosomal dominant 13 -> [Intellectual developmental disorder, autosomal dominant 13](https://www.uniprot.org/diseases/DI-03425)
- Mental retardation, autosomal dominant 2 -> [Intellectual developmental disorder, autosomal dominant 2](https://www.uniprot.org/diseases/DI-03185)
- Mental retardation, autosomal dominant 20 -> [Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language](https://www.uniprot.org/diseases/DI-02856)
- Mental retardation, autosomal dominant 21 -> [Intellectual developmental disorder, autosomal dominant 21](https://www.uniprot.org/diseases/DI-03927)
- Mental retardation, autosomal dominant 22 -> [Intellectual developmental disorder, autosomal dominant 22](https://www.uniprot.org/diseases/DI-03970)
- Mental retardation, autosomal dominant 23 -> [Intellectual developmental disorder, autosomal dominant 23](https://www.uniprot.org/diseases/DI-04067)
- Mental retardation, autosomal dominant 26 -> [Intellectual developmental disorder, autosomal dominant 26](https://www.uniprot.org/diseases/DI-04120)
- Mental retardation, autosomal dominant 29 -> [Intellectual developmental disorder, autosomal dominant 29](https://www.uniprot.org/diseases/DI-04252)
- Mental retardation, autosomal dominant 3 -> [Intellectual developmental disorder, autosomal dominant 3](https://www.uniprot.org/diseases/DI-00711)
- Mental retardation, autosomal dominant 30 -> [Intellectual developmental disorder, autosomal dominant 30](https://www.uniprot.org/diseases/DI-04257)
- Mental retardation, autosomal dominant 33 -> [Intellectual developmental disorder, autosomal dominant 33](https://www.uniprot.org/diseases/DI-04391)
- Mental retardation, autosomal dominant 34 -> [Intellectual developmental disorder, autosomal dominant 34](https://www.uniprot.org/diseases/DI-04418)
- Mental retardation, autosomal dominant 35 -> [Intellectual developmental disorder, autosomal dominant 35](https://www.uniprot.org/diseases/DI-04419)
- Mental retardation, autosomal dominant 36 -> [Intellectual developmental disorder, autosomal dominant 36](https://www.uniprot.org/diseases/DI-04420)
- Mental retardation, autosomal dominant 38 -> [Intellectual developmental disorder, autosomal dominant 38](https://www.uniprot.org/diseases/DI-04443)
- Mental retardation, autosomal dominant 4 -> [Intellectual developmental disorder, autosomal dominant 4](https://www.uniprot.org/diseases/DI-00712)
- Mental retardation, autosomal dominant 40 -> [Intellectual developmental disorder, autosomal dominant 40](https://www.uniprot.org/diseases/DI-04513)
- Mental retardation, autosomal dominant 41 -> [Intellectual developmental disorder, autosomal dominant 41](https://www.uniprot.org/diseases/DI-04716)
- Mental retardation, autosomal dominant 43 -> [Intellectual developmental disorder, autosomal dominant 43](https://www.uniprot.org/diseases/DI-04747)
- Mental retardation, autosomal dominant 45 -> [Intellectual developmental disorder, autosomal dominant 45](https://www.uniprot.org/diseases/DI-05061)
- Mental retardation, autosomal dominant 46 -> [Intellectual developmental disorder, autosomal dominant 46](https://www.uniprot.org/diseases/DI-05062)
- Mental retardation, autosomal dominant 47 -> [Intellectual developmental disorder, autosomal dominant 47](https://www.uniprot.org/diseases/DI-05063)
- Mental retardation, autosomal dominant 48 -> [Intellectual developmental disorder, autosomal dominant 48](https://www.uniprot.org/diseases/DI-05131)
- Mental retardation, autosomal dominant 5 -> [Intellectual developmental disorder, autosomal dominant 5](https://www.uniprot.org/diseases/DI-00713)
- Mental retardation, autosomal dominant 51 -> [Intellectual developmental disorder, autosomal dominant 51](https://www.uniprot.org/diseases/DI-05152)
- Mental retardation, autosomal dominant 52 -> [Intellectual developmental disorder, autosomal dominant 52](https://www.uniprot.org/diseases/DI-05153)
- Mental retardation, autosomal dominant 53 -> [Intellectual developmental disorder, autosomal dominant 53](https://www.uniprot.org/diseases/DI-05154)
- Mental retardation, autosomal dominant 54 -> [Intellectual developmental disorder, autosomal dominant 54](https://www.uniprot.org/diseases/DI-05155)
- Mental retardation, autosomal dominant 57 -> [Intellectual developmental disorder, autosomal dominant 57](https://www.uniprot.org/diseases/DI-05289)
- Mental retardation, autosomal dominant 58 -> [Intellectual developmental disorder, autosomal dominant 58](https://www.uniprot.org/diseases/DI-05326)
- Mental retardation, autosomal dominant 6, with or without seizures -> [Intellectual developmental disorder, autosomal dominant 6, with or without seizures](https://www.uniprot.org/diseases/DI-03128)
- Mental retardation, autosomal dominant 7 -> [Intellectual developmental disorder, autosomal dominant 7](https://www.uniprot.org/diseases/DI-03186)
- Mental retardation, autosomal recessive 1 -> [Intellectual developmental disorder, autosomal recessive 1](https://www.uniprot.org/diseases/DI-00714)
- Mental retardation, autosomal recessive 13 -> [Intellectual developmental disorder, autosomal recessive 13](https://www.uniprot.org/diseases/DI-02585)
- Mental retardation, autosomal recessive 14 -> [Intellectual developmental disorder, autosomal recessive 14](https://www.uniprot.org/diseases/DI-03192)
- Mental retardation, autosomal recessive 2A -> [Intellectual developmental disorder, autosomal recessive 2](https://www.uniprot.org/diseases/DI-00715)
- Mental retardation, autosomal recessive 3 -> [Intellectual developmental disorder, autosomal recessive 3](https://www.uniprot.org/diseases/DI-00716)
- Mental retardation, autosomal recessive 34, with variant lissencephaly -> [Intellectual developmental disorder, autosomal recessive 34, with variant lissencephaly](https://www.uniprot.org/diseases/DI-03395)
- Mental retardation, autosomal recessive 36 -> [Neurodevelopmental disorder with brain abnormalities, poor growth, and dysmorphic facies](https://www.uniprot.org/diseases/DI-03799)
- Mental retardation, autosomal recessive 37 -> [Intellectual developmental disorder, autosomal recessive 37](https://www.uniprot.org/diseases/DI-03943)
- Mental retardation, autosomal recessive 38 -> [Intellectual developmental disorder, autosomal recessive 38](https://www.uniprot.org/diseases/DI-03939)
- Mental retardation, autosomal recessive 40 -> [Neurodevelopmental disorder with feeding difficulties, thin corpus callosum, and foot deformity](https://www.uniprot.org/diseases/DI-04004)
- Mental retardation, autosomal recessive 41 -> [Intellectual developmental disorder, autosomal recessive 41](https://www.uniprot.org/diseases/DI-04038)
- Mental retardation, autosomal recessive 42 -> [Neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities](https://www.uniprot.org/diseases/DI-04086)
- Mental retardation, autosomal recessive 44 -> [Intellectual developmental disorder, autosomal recessive 44](https://www.uniprot.org/diseases/DI-04192)
- Mental retardation, autosomal recessive 45 -> [Intellectual developmental disorder, autosomal recessive 45](https://www.uniprot.org/diseases/DI-04220)
- Mental retardation, autosomal recessive 46 -> [Intellectual developmental disorder, autosomal recessive 46](https://www.uniprot.org/diseases/DI-04283)
- Mental retardation, autosomal recessive 47 -> [Intellectual developmental disorder, autosomal recessive 47](https://www.uniprot.org/diseases/DI-04311)
- Mental retardation, autosomal recessive 48 -> [Intellectual developmental disorder, autosomal recessive 48](https://www.uniprot.org/diseases/DI-04357)
- Mental retardation, autosomal recessive 5 -> [Intellectual developmental disorder, autosomal recessive 5](https://www.uniprot.org/diseases/DI-03476)
- Mental retardation, autosomal recessive 50 -> [Intellectual developmental disorder, autosomal recessive 50](https://www.uniprot.org/diseases/DI-04481)
- Mental retardation, autosomal recessive 51 -> [Intellectual developmental disorder, autosomal recessive 51](https://www.uniprot.org/diseases/DI-04633)
- Mental retardation, autosomal recessive 52 -> [Intellectual developmental disorder, autosomal recessive 52](https://www.uniprot.org/diseases/DI-04697)
- Mental retardation, autosomal recessive 54 -> [Intellectual developmental disorder, autosomal recessive 54](https://www.uniprot.org/diseases/DI-04760)
- Mental retardation, autosomal recessive 56 -> [Intellectual developmental disorder, autosomal recessive 56](https://www.uniprot.org/diseases/DI-04823)
- Mental retardation, autosomal recessive 59 -> [Intellectual developmental disorder, autosomal recessive 59](https://www.uniprot.org/diseases/DI-04942)
- Mental retardation, autosomal recessive 60 -> [Intellectual developmental disorder, autosomal recessive 60](https://www.uniprot.org/diseases/DI-04989)
- Mental retardation, autosomal recessive 61 -> [Intellectual developmental disorder, autosomal recessive 61](https://www.uniprot.org/diseases/DI-05133)
- Mental retardation, autosomal recessive 63 -> [Intellectual developmental disorder, autosomal recessive 63](https://www.uniprot.org/diseases/DI-05317)
- Mental retardation, autosomal recessive 64 -> [Intellectual developmental disorder, autosomal recessive 64](https://www.uniprot.org/diseases/DI-05318)
- Mental retardation, autosomal recessive 65 -> [Intellectual developmental disorder, autosomal recessive 65](https://www.uniprot.org/diseases/DI-05327)
- Mental retardation, autosomal recessive 66 -> [Intellectual developmental disorder, autosomal recessive 66](https://www.uniprot.org/diseases/DI-05434)
- Mental retardation, autosomal recessive 7 -> [Intellectual developmental disorder, autosomal recessive 7](https://www.uniprot.org/diseases/DI-00717)
- Mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma -> [Intellectual disability, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma](https://www.uniprot.org/diseases/DI-03642)
- Mental retardation, truncal obesity, retinal dystrophy, and micropenis -> [Intellectual disability, truncal obesity, retinal dystrophy, and micropenis](https://www.uniprot.org/diseases/DI-02533)
- Mental retardation, X-linked 3 -> [Methylmalonic aciduria and homocystinuria, cblX type](https://www.uniprot.org/diseases/DI-03561)
- Mental retardation, X-linked 45 -> [Intellectual developmental disorder, X-linked 45](https://www.uniprot.org/diseases/DI-00730)
- Mental retardation, X-linked 46 -> [Intellectual developmental disorder, X-linked 46](https://www.uniprot.org/diseases/DI-00731)
- Mental retardation, X-linked 88 -> [Intellectual developmental disorder, X-linked 88](https://www.uniprot.org/diseases/DI-03180)
- Mental retardation, X-linked 89 -> [Intellectual developmental disorder, X-linked 89](https://www.uniprot.org/diseases/DI-00735)
- Mental retardation, X-linked 91 -> [Intellectual developmental disorder, X-linked 91](https://www.uniprot.org/diseases/DI-00737)
- Mental retardation, X-linked 92 -> [Intellectual developmental disorder, X-linked 92](https://www.uniprot.org/diseases/DI-00738)
- Mental retardation, X-linked 95 -> [Intellectual developmental disorder, X-linked 95](https://www.uniprot.org/diseases/DI-00740)
- Mental retardation, X-linked, syndromic, Martin-Probst type -> [Martin-Probst syndrome](https://www.uniprot.org/diseases/DI-03524)
- Mental retardation-hypotonic facies syndrome, X-linked, 1 -> [Intellectual disability-hypotonic facies syndrome, X-linked, 1](https://www.uniprot.org/diseases/DI-00723)
- Mental retardation with language impairment and autistic features -> [Intellectual disability with language impairment and autistic features](https://www.uniprot.org/diseases/DI-02984)
- Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation -> [Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability](https://www.uniprot.org/diseases/DI-03432)
- Myopia 27 -> [Myopia 27, autosomal dominant](https://www.uniprot.org/diseases/DI-05775)
- Nephrolithiasis 1 -> [Nephrolithiasis, X-linked recessive, with renal failure](https://www.uniprot.org/diseases/DI-00801)
- Nephrolithiasis 2 -> [Dent disease 1](https://www.uniprot.org/diseases/DI-00802)
- Optic atrophy 10 with or without ataxia, mental retardation, and seizures -> [Optic atrophy 10 with or without ataxia, intellectual disability, and seizures](https://www.uniprot.org/diseases/DI-04624)
- Parkinsonism-dystonia infantile -> [Parkinsonism-dystonia 1, infantile-onset](https://www.uniprot.org/diseases/DI-02782)
- Parkinsonism-dystonia, infantile, 2 -> [Parkinsonism-dystonia 2, infantile-onset](https://www.uniprot.org/diseases/DI-05288)
- Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis -> [Neurodevelopmental disorder with spasticity, hypomyelinating leukodystrophy, and brain abnormalities](https://www.uniprot.org/diseases/DI-04528)
- Renal tubular acidosis, proximal, with ocular abnormalities and mental retardation -> [Renal tubular acidosis, proximal, with ocular abnormalities and intellectual disability](https://www.uniprot.org/diseases/DI-02226)
- Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance -> [Seizures, sensorineural deafness, ataxia, intellectual disability, and electrolyte imbalance](https://www.uniprot.org/diseases/DI-02543)
- Skeletal defects, genital hypoplasia, and mental retardation -> [Skeletal defects, genital hypoplasia, and impaired intellectual development](https://www.uniprot.org/diseases/DI-02310)
- Sotos syndrome 1 -> [Sotos syndrome](https://www.uniprot.org/diseases/DI-02318)
- Sotos syndrome 2 -> [Malan syndrome](https://www.uniprot.org/diseases/DI-03506)
- Sotos syndrome 3 -> [Intellectual developmental disorder, autosomal recessive 74](https://www.uniprot.org/diseases/DI-04855)
- Spastic paraplegia 49, autosomal recessive -> [Neuropathy, hereditary sensory and autonomic, 9, with developmental delay](https://www.uniprot.org/diseases/DI-03681)
- Stueve-Wiedemann syndrome -> [Stuve-Wiedemann syndrome](https://www.uniprot.org/diseases/DI-02344)
- Teebi hypertelorism syndrome -> [Teebi hypertelorism syndrome 1](https://www.uniprot.org/diseases/DI-05364)

Deleted diseases

- Brachydactyly-mental retardation syndrome
- Neuropathy, hereditary, with or without age-related macular degeneration
- Opitz GBBB syndrome 2

## Changes to the [controlled vocabulary for PTMs](https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/docs/ptmlist)

New term for the feature key 'Cross-link' ('CROSSLNK' in the flat file):

- Dityrosine (Tyr-Tyr) (interchain with Y-...)

New term for the feature key 'Modified residue' ('MOD_RES' in the flat file):

- ADP-ribosylhistidine

## Changes to [keywords](https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/docs/keywlist)

Modified keyword:

- Mental retardation -> [Intellectual disability](https://www.uniprot.org/keywords/KW-0991)
